Treatment of cardiac dysfunction

Patent metadata

Field	Value
Publication number	US-12409322-B2
Application number	US-202217808087-A
Country	US
Kind code	B2
Filing date	Jun 21, 2022
Priority date	Aug 26, 2016
Publication date	Sep 9, 2025
Grant date	Sep 9, 2025

Abstract

Modulation, preferably inhibition, of neurosignaling of a cardiac-related sympathetic nerve in the extracardiac intrathoracic neural circuit is effective in stabilizing cardiac electrical and/or mechanical function, thereby providing ways of treating or preventing cardiac dysfunction such as arrhythmias.

First claim

The invention claimed is:

1. A device for reversibly inhibiting neural activity of a subject's cardiac-related sympathetic nerve in the extracardiac intrathoracic neural circuit of the subject, the device comprising:
at least one electrode configured to be placed on or around a cardiac-related sympathetic nerve at the ansae subclaviae or at a site along the paravertebral chain between the T1 and T2 ganglia; and
a controller configured to electrically communicate with the at least one electrode, wherein the controller is configured to deliver a therapeutic electrical signal to the at least one electrode,
wherein the therapeutic electrical signal is a kilohertz frequency alternating current (KHFAC) signal or a charge-balanced direct current (DC) signal,
wherein the therapeutic electrical signal is configured to produce a physiological response in the subject, and
wherein the physiological response is a decrease in one or more of at least chronotropic, dromotropic, lusitropic, or inotropic evoked responses.

2. The device of claim 1 , wherein the DC signal comprises a cathodic pulse and an anodic pulse.

3. The device of claim 2 , wherein the cathodic pulse comprises a current between and including 0.1 mA and 10 mA.

4. The device of claim 1 , wherein the KHFAC signal comprises a frequency from 2 kHz to 30 kHz.

5. The device of claim 1 , wherein the therapeutic electrical signal is a charge-balanced direct current carousel (CBDCC) signal, or a hybrid of KHFAC and CBDCC.

6. The device of claim 5 , wherein the electrical signal comprises a DC ramp and a KHFAC waveform that commences during the DC ramp.

7. The device of claim 5 , wherein the therapeutic electrical signal comprises, sequentially:
a DC ramp followed by a plateau and charge-balancing;
a first AC waveform, wherein an amplitude of the first AC waveform increases during a period that the waveform is applied; and
a second AC waveform having a lower frequency and/or lower amplitude than the first waveform.

8. The device of claim 1 , wherein the cardiac-related sympathetic nerve is inhibited unilaterally or bilaterally.

9. The device of claim 1 , wherein the inhibition is full block or a partial block.

10. The device of claim 1 , wherein the at least one electrode is a carousel electrode comprising a plurality of electrode contacts.

11. The device of claim 10 , wherein at least one of the plurality of electrode contacts is in signaling contact with the cardiac-related sympathetic nerve.

12. The device of claim 10 , wherein the controller is further configured to deliver the therapeutic electrical signal to each of the plurality of electrode contacts in a repeating cycle.

13. The device of claim 10 , wherein each of the plurality of electrode contacts is electrically coupled to its own current source or voltage source.

14. The device of claim 13 , wherein the controller is further configured to adjust an amplitude of the therapeutic electrical signal delivered to each of the plurality of electrode contacts independently of other electrode contacts.

15. The device of claim 1 , wherein the controller is further configured to deliver the therapeutic electrical signal periodically.

16. The device of claim 10 , wherein the device comprises at least one sensor configured to detect a physiological parameter related to electrical activity of the heart of a subject, and wherein the sensor is configured to generate a signal indicative of the physiological parameter.

17. The device of claim 16 , wherein the electrical activity of the heart of the subject is indicative of cardiac dysfunction or abnormal heart rhythm.

18. The device of claim 16 , wherein the controller is further configured to:
receive the physiological signal originating from the sensor;
determine the physiological parameter based at least in part on the physiological signal;
determine whether the physiological parameter meets or exceeds a threshold; and
based on the determination that the physiological parameter meets or exceeds the threshold, deliver the therapeutic electrical signal to the at least one electrode.

19. The device of claim 16 , wherein the physiological parameter includes one or more of at least heart rate variability, heart rate turbulence, baroreflex sensitivity, heart rate deceleration capacity, or T wave alternans.

20. The device of claim 1 , wherein the device is configured for treatment or prevention of one or more of at least heart failure, myocardial infarction, cardiac arrythmias, or ventricular arrhythmias.

Assignees

• Univ California
• Presidio Medical Inc

Inventors

• Ardell Jeffrey Laurence
• Shivkumar Kalyanam
• Sridhar Arun

Classifications

• A61N1/36171

  Frequency · CPC title

• A61N1/36157

  Current (A61N1/3616 takes precedence) · CPC title

• A61N1/36139

  with automatic adjustment · CPC title

• A61N1/0551

  Spinal or peripheral nerve electrodes · CPC title

• A61N1/362

  Heart stimulators (heart defibrillators A61N1/39) · CPC title